NCT06401343: Use of SGLT2i in noHCM With HFpEF
- State
- State not given
- Phase
- Phase 4
- People
- 94 planned
- Started
- 1 Aug 2022
- Primary completion
- 1 Aug 2024
- Arms
- Study group
- Results
- None posted
- 1 Aug 2022: Trial started
- 6 May 2024: Trial registered
A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set
Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.
Kind of treatment: Drug.
Also known as Empagliflozin 10 MG, Empagliflozin 10 MG OD, Empagliflozin 25 MG, Empagliflozin10Mg Tab, Glyxambi component empagliflozin, Jardiance, Trijardy xr component empagliflozin.
Registries searched: ClinicalTrials.gov, through 17 Nov 2026.